Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Novartis
Boehringer Ingelheim
Teva
US Army
Harvard Business School
Daiichi Sankyo
Fish and Richardson
Argus Health
UBS

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020254

« Back to Dashboard

NDA 020254 describes VOLTAREN-XR, which is a drug marketed by Novartis and is included in one NDA. It is available from seven suppliers. Additional details are available on the VOLTAREN-XR profile page.

The generic ingredient in VOLTAREN-XR is diclofenac sodium. There are forty-seven drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
Summary for 020254
Tradename:VOLTAREN-XR
Applicant:Novartis
Ingredient:diclofenac sodium
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Dermatological Agents
Ophthalmic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020254
Suppliers and Packaging for NDA: 020254
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOLTAREN-XR diclofenac sodium TABLET, EXTENDED RELEASE;ORAL 020254 NDA AUTHORIZED GENERIC Sandoz Inc 0781-1381 N 0781-1381-01
VOLTAREN-XR diclofenac sodium TABLET, EXTENDED RELEASE;ORAL 020254 NDA AUTHORIZED GENERIC RxChange Co. 33358-451 E 33358-451-30

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 8, 1996TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
Moodys
Mallinckrodt
Baxter
AstraZeneca
Queensland Health
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot